KR860000871A - Site-Enhanced Azalea Compounds of Radionuclides and Their Uses - Google Patents

Abstract

No content

Description

Site-Enhanced Azalea Compounds of Radionuclides and Their Uses

As this is a public information case, the full text was not included.

Claims (296)

Among the group consisting of amines, carboxyls, hydroxyls, amides and imides, sundigodi have at least one reactive photofunctional group, but they may (a) form chelates with metallic radionuclides or (b) chelate with radioactive nuclides of the intertidal mass. A chelating moiety having a functional group which is not essential for the complex-forming property of the chelating agent which forms a chelating agent, wherein at least one of the reactive functional groups of the chelating agent has no hydrogen atom, and (2) dihydro Pyridine A synthetic material comprising a pyridinium salt redox carrier component, wherein a chelate residue and a carrier component are bonded to each other to form a bond that can be cleaved by hydrolysis therebetween. Salts having the structure In the above expression -May form chelates with metallic radionuclides and have at least one reactive functional group selected from the group consisting of amino, carboxyl, hydroxyl, amide and imide but not essential to the complex-forming properties of the chelating agent A moiety in a chelating agent having at least one moiety characterized in that at least one of the reactive functional groups of the chelating agent lacks one hydrogen atom, y is 1 or 2, [QC ⁺ ] is hydrophilic and forms an ionic pyridinium salt Dihydropyridine Is a pyridinium salt redox carrier, X ⁻ is an anion of a pharmaceutically acceptable inorganic or organic acid, n is the valence of the acid anion, and m is the number equal to y when multiplied by n. The salt with a residue according to claim 2 wherein at least one of the amino or hydroxyl functional groups of the chelating agent is free of one hydrogen atom. 4. The salt of claim 3 wherein y is one. The salt of claim 3 wherein [QC ⁺ ] is a radical of the formula In the above formula, the alkylene group is one to three linear or branched carbon atoms, R ₀ is the same radical as the compatible part of the natural amino acid, and P is 0, 1 or 2, and P is 2 , Alkylene groups are the same or different, radicals are the same or different, R ₁ is C ₁ -C ₇ alkyl, C ₁ -C ₇ alkyl or C ₇ -C ₁₀ aralkyl, R ₃ is C ₁ -C ₃ alkylene, X is -CONR′R ″ (where R ′ and R ″ are the same or different and are each H or C ₁ -C ₇ alkyl) or -CH = NOR ′ ″ where R ′ ″ is H or C ₁ -C ₇ alkyl). And a group having a carbonyl group of formulas (a) and (c) and an X substituent group of formula (b) are each bonded at the 2, 3 or 4 position of the pyridinium ring, and carbonyl of the formulas (d) and (f) X substituent of the group and the structural formula (e) is bonded to the 2, 3 or 4 position of the quinolinium ring, respectively, a group having a carbonyl of the formula (g) and (j) and X of the formula (h) Substituents are bonded at the 1, 3, or 4 positions of the isoquinolinium ring, respectively. The salt of claim 5 wherein P is zero. The compound of claim 5, wherein P is 1, alkylene is —CH ₂ — and R ₀ is H, —CH ₃ , —CH (CH ₃ ) ₂ , —CH ₂ CH (CH ₃ ) ₂ , ,-(CH ₂ ) ₂ -SCH ₃ , -CH ₂ -CONH ₂ or -CH ₂ CH ₂ -CONH ₂ . 3. A salt with a residue according to claim 2 characterized by the absence of one hydrogen atom in the -NH- component which is part of an amide functional group or an imide functional group or is a primary or secondary amino functional group having a low pka. The salt of claim 8, wherein y is 1. The salt according to claim 8, wherein [QC ⁺ ] is a radical of the formula In the above formula, the alkylene group is one to three linear or branched carbon atoms, R ₀ is the same radical as the compatible part of the natural amino acid, and P is 0, 1 or 2, when P is alkyl The ethylene groups are the same or different and the R ₀ radicals are the same or different, R ₁ is C ₁ -C ₇ alkyl, C ₁ -C ₇ haloalkyl or C ₇ -C ₁₀ aralkyl, R is hydrogen, C _1- C ₇ alkyl, C ₃ -C ₈ cycloalkyl, C ₁ -C ₇ haloalkyl, furyl, phenyl or one or more halo, lower alkyl, lower alkoxy, carbamoyl, lower alkoxy carbonyl, lower alkanoyloxy, lower Phenyl substituted with low alkyl, mono (lower alkyl) carbamoyl, di (lower alkyl) carbamoyl, lower alkylthio, lower alkylsulfinyl or lower alkylsulfonyl, R ₃ is C ₁ -C ₃ alkylene and, X is -CONR'R "(where R 'and R" are either the same or different and are each H or C ₁ -C ₇ alkyl) -CH = NOR'"(wherein R '" is H In A C ₁ -C ₇ alkyl). And a group having a carbonyl group of formulas (K) and (m) and an X substituent group of formula (1) are each bonded at the 2, 3 or 4 position of the pyridinium ring, and carbonyl of the formulas (n) and (p) X substituent of the group and the structural formula (o) is bonded to the 2, 3 or 4 position of the quinolinium ring, respectively, the group having the carbonyl of the formula (q) and (s) and X of the formula (r) Substituents are bonded at the 1, 3, or 4 positions of the isoquinolinium ring, respectively. The salt of claim 10 wherein P is zero. The compound of claim 10 wherein P is 0, alkylene is -CH ₂ -and R ₀ is H, -CH ₃ , -CH (CH ₃ ) ₂ , -CH ₂ CH (CH ₃ ) ₂ , ,-(CH ₂ ) ₂ -SCH ₃ , -CH ₂ -CONH ₂ or -CH ₂ CH ₂ -CONH ₂ . The salt with a residue according to claim 2 wherein at least one reactive -COOH functional group of the chelating agent is free of one hydrogen atom. The salt of claim 13, wherein y is 1. The salt of claim 13 wherein [QC ⁺ ] is a radical of the formula Wherein the alkylene group is one to three carbon atoms with a straight or branched chain, R ₀ is the same radical as the corresponding moiety of the natural amino acid, and P is 0, 1 or 2, where P is 2 , Alkylene groups are the same or different, R ₀ radicals are the same or different, Z ′ is C ₁ -C ₈ straight or branched alkylene, Q is —0- or —NH—, and R ₁ is C ₁ -C ₇ alkyl, C ₁ -C ₇ haloalkyl or C ₇ -C ₁₀ aralkyl, R ₃ is C ₁ -C ₃ alkylene, X is -CONR′R ″ where R ′ and R ″ Are the same or different and are each H or C ₁ -C ₇ alkyl) or -CH = NOR '"where R' is the same or different and are each H or C ₁ -C ₇ alkyl. And the X substituent group of formula (ii) and the group having carbonyl of formula (iii) and (iii) are each bonded to the 2, 3 or 4 position of the pyridinium ring, and the X substituent group of the formula (v) ) And (ⅵ) carbonyl groups are bonded to the 2, 3 or 4 position of the quinolinium ring, respectively, and have an X substituent of the formula (iii) and a carbonyl of the formulas (iii) and (ix). The groups are bonded at the 1, 3, or 4 positions of the isoquinolinium ring, respectively. 15. The salt of claim 14, wherein [QC ⁺ ] is a radical of the formula: or In the above expression Is the skeleton of the sugar molecule, n ^iv is a positive integer equal to the total number of -OH groups of the sugar molecule from which the skeleton is derived, and n ^v is the total -OH group of the sugar molecule from which the skeleton is derived. An integer of one less than a number (+) and A in structural formulas (xii), (xiii) and (xiv) are each hydroxy or D ', where D' is -COOH of a chelating agent with one reactive -COOH functional group It is a residue characterized by lacking one hydrogen atom in a functional group. And R ' ₄ in the formulas (x) and (xi) are each hydroxy or one of the following: In the above formula, the alkylene group is one to three linear or branched carbon atoms, R ₀ is the same radical as the compatible moiety of the natural amino acid, and P is 0, 1 or 2, and P is 2 , Alkylene groups are the same or different, R ₀ radicals are the same or different, D ′ is as defined in formulas (xii), (xiii) and (xiv), R ₁ is C ₁ -C ₇ alkyl, Or C ₁ -C ₇ haloalkyl or C ₇ -C ₁₀ arylalkyl, the group having the carbonyl group represented by each structural formula attached to the 2, 3, or 4 position of pyridinium ring or quinolinium ring or isoqui In the 1, 3, or 4 position of the noisy ring. Provided that at least one of R ₄ ′ in (xi) of formula (x) is one of the formulas. (As defined above with respect to the position of the group having alkylene, R _O , P and R ₁ and carbonyl in the formula above) and at least one R ₄ ′ for a given compound has In the case of a group, all carbonyl groups in this compound are identical. The salt of claim 15, wherein P is zero. The salt of claim 16, wherein P is zero. The compound of claim 15, wherein P is 0, alkylene is -CH ₂ -and R ₀ is H, -CH ₃ , -CH (CH ₃ ) ₂ , -CH ₂ CH (CH ₃ ) ₂ , | ,-(CH ₂ ) ₂ -SCH ₃ , -CH ₂ -CONH ₂ or -CH ₂ CH ₂ -CONH ₂ . Or a pharmaceutically acceptable non-toxic salt thereof. In the above expression -May form chelates with metallic radionuclides and have at least one reactive functional group selected from the group consisting of amino, carboxyl, hydroxyl, amide and imide but not essential to the complex-forming properties of the chelating agent A residue in a chelating agent, wherein the residue is characterized in that at least one of the reactive functional groups of the chelating agent is free of one hydrogen atom, y is 1 or 2, and [DHC] is a blood brain barrier permeable to biooxidation. Dihydropyridine in reduced form Pyridinium salt redox carrier. 21. A compound with a residue according to claim 20, wherein at least one of the amino or hydroxyl reactive functional groups of the chelating agent is free of one hydrogen atom. The compound of claim 21, wherein y is 1. 22. A compound according to claim 21, wherein [DHC] is a radical of the formula In the above formula, the alkylene group is one to three linear or branched carbon atoms, R ₀ is the same radical as the compatible moiety of the natural amino acid, and P is 0, 1 or 2, and P is 2 , Alkylene groups are the same or different and R0 radicals are the same or different, and the dotted lines in the structural formulas (a '), (b') and (c ') are double-bonded at either the 4 or 5 position of the dihydropyridine ring. A dashed line in the formulas (d ′), (e ′) and (f ′) indicates that there is a double bond in either the 2 or 3 position of the dihydroquinoline ring, R ₁ is C ₁ -C ₇ alkyl, C ₁ -C ₇ haloalkyl or C ₇ -C ₁₀ aralkyl, R ₃ is C ₁ -C ₃ alkylene and X is -CONR′R ″ where R ′ and R ″ are the same Or different and H or C ₁ -C ₇ alkyl, respectively, or -CH = NOR ′ ″ where R ″ is H or C ₁ -C ₇ alkyl. And the group having a carbonyl group of the formulas (a ') and (c') and the X substituents of the formula (b ') are each bonded to the 2, 3 or 4 positions of the dihydropyridone ring, and the formula (d') And the group having the carbonyl of (f ′) and the X substituent of the structural formula (o ′) are bonded at the 2, 3, or 4 positions of the dihydroquinoline ring, respectively, and carbonyl of the structural formulas (g ′) and (j ′). And the X substituent of the formula (h ') is bonded to the 1, 3 or 4 position of the dihydroisoquinoline ring, respectively. The compound of claim 23, wherein P is zero. The compound of claim 23, wherein P is 0, alkylene is —CH ₂ —, R ₀ is H, —CH ₃ , —CH (CH ₃ ) ₂ , —CH ₂ CH (CH ₃ ) ₂ , ,-(CH ₂ ) ₂ -SCH ₃ , -CH ₂ -CONH ₂ or -CH ₂ CH ₂ -CONH ₂ . A compound with a moiety as claimed in claim 20 which is free of one hydrogen atom in the -NH-component which is part of an amide functional group or an imide functional group or part of a primary or secondary amino functional group having a low pKa. The compound of claim 26, wherein y is 1. The compound of claim 26, wherein [DHC] is a radical of the structure: In the above formula, the alkylene group is 1 to 3 carbon atoms with straight or branched chain, R _O is the same radical as the corresponding part of the natural amino acid, P is 0, 1 or 2, and P is 2 , Alkylene groups are the same or different, R ₀ radicals are the same or different, and R is hydrogen, C ₁ -C ₇ alkyl, C ₃ -C ₈ cycloalkyl, C ₁ -C ₇ haloalkyl, furyl, phenyl One or more halo, lower alkyl, lower alkoxy, carbamoyl, lower alkoxycarbonyl, lower alkanoyloxy, lower haloalkyl, mono (lower alkyl) carbamoyl, di (lower alkyl) carbamoyl, lower alkylthio , Lower alkylsulfinyl or lower alkylsulfonyl-substituted phenyl, and the dashed lines in structural formulas (k '), (l') and (m ') are double-bonded at either the 4 or 5 position of the dihydropyridine ring. Dashed lines in the structural formulas (n '), (o') and (p ') represent 2 degrees of the dihydroquinoline ring. Represents one double bond in any of the 3 positions, R ₁ is C ₁ -C ₇ alkyl, C ₁ -C ₇ haloalkyl or C ₇ -C ₁₀ aralkyl, and R ₃ is C ₁ -C ₃ Alkylene, where X is -CONR′R ″ (where R ′ and R ″ are the same or different and are each H or C ₁ -C ₇ alkyl) or -CH = NOR ′ ″ where R ″ ′ is H or C ₁ -C ₇ alkyl). And the group having a carbonyl group of the formulas (k ') and (m') and the X substituents of the formula (1 ') are each bonded at the 2, 3 or 4 position of the dihydropyridine ring, and the formulas (n') and ( p ′) group with carbonyl and X substituent of formula (o ′) are bonded to 2, 3 or 4 position of dihydroquinolin ring, respectively, and carbonyl of formulas (g ′) and (s ′) And the X substituents of the formula (r ') are bonded to the 1, 3 or 4 positions of the dihydroisoquinoline ring, respectively. The compound of claim 28, wherein P is zero. The compound of claim 28, wherein P is 0, alkylene is —CH ₂ —, R ₀ is H, —CH ₃ , —CH (CH ₃ ) ₂ , —CH ₂ CH (CH ₃ ) ₂ , ,-(CH ₂ ) ₂ -SCH ₃ , -CH ₂ -CONH ₂ or -CH ₂ CH ₂ -CONH ₂ . A compound with a moiety according to claim 20 wherein there is no one hydrogen atom in at least one carboxyl functional group of the chelating agent. The compound of claim 31, wherein y is 1. 32. The compound of claim 31, wherein [DHC] is a radical of the formula: In the above formula, the alkylene group is linear or branched carbon atoms 1-3, R ₀ is the same radical as the corresponding part of the natural amino acid, P is 0, 1 or 2, when P is 2 , Alkylene groups are the same or different, and R ₀ radicals are the same or different. And the dotted lines in the formulas (i ') (ii') and (x ') indicate that there is a double bond in either the 4 or 5 position of the dihydropyridine ring, and And the dotted lines in (ⅵ ′) indicate that there is a double bond in either the 2 or 3 position of the dihydroquinoline ring, Z ′ is C ₁ -C ₈ straight or branched alkylene, and Q is − O- or -NH-, R ₁ is C ₁ -C ₇ alkyl, C ₁ -C ₇ haloalkyl or C ₇ -C ₁₀ aralkyl, R ₃ is C ₁ -C ₃ alkylene, and X is- CONR′R ″ (where R ′ and R ″ are the same or different and are each H or C ₁ -C ₇ alkyl) or —CH = NOR ′ ″ where R ″ is H or C ₁ -C ₇ alkyl. In addition, the X substituent of the formula (ii ') and the group having a carbonyl of the formulas (VII') and (VII ') are each bonded to the 2, 3 or 4 positions of the dihydropyridine ring, and The X substituent and the group having the carbonyl of the formulas (VII ') and (VII') are each bonded to the 2, 3 or 4 positions of the dihydroquinoline ring, and the X substituent of the formula (VIIiii) and the structural formula (VII) And the group having a carbonyl of (ⅸ ′) is bonded to the 1, 3 or 4 position of the dihydroisoquinoline ring, respectively. 33. A compound according to claim 32, wherein [DHC] is a radical of the formula In the above formula, the alkylene group is one to three linear or branched carbon atoms, R ₀ is the same radical as the corresponding part of the natural amino acid, and P is 0, 1 or 2, and P is 2 , Alkylene groups are the same or different and the R ₀ radicals are the same or different. And the dotted line in the structural formula (Xii ') indicates that there is a double bond in any one of 4 or 5 positions of the dihydropyridine ring, and the dotted line in the structural formula (XIII') indicates either the 2 or 3 position of the dihydroquinoline ring. Is a skeleton of sugar molecule, n ^iv is a positive integer equal to the total number of -OH groups of the sugar molecule from which this skeleton is derived, and n ^v is the skeleton from which this skeleton is derived It is an integer that is one less than the total number of -OH groups in the sugar molecule. In addition, A in structural formulas (Xii '), (Xiii'), (xiv ') and (xiv ") is hydroxy or D', respectively, and D 'is a chelating -COOH functional group having one reactive -COOH function. It is a residue characterized by the absence of one hydrogen atom. And R ₄ in the formulas (x ') and (xi') are each hydroxy or one of the following: In the above formula, the alkylene group is one to three linear or branched carbon atoms, R ₀ is the same radical as the corresponding part of the natural amino acid, and P is 0, 1 or 2, and P is 2 , The alkylene group is the same or different and the R ₀ radical is the same or different, and the dotted line is as defined in the structural formulas (ⅹii ') and (ⅹiii'), and D 'is the structural formula (ⅹii'), (ⅹiii '), As defined in (iviv), R ₁ is C ₁ -C ₇ alkyl, C ₁ -C ₇ haloalkyl or C ₇ -C ₁₀ aralkyl. Also shown is a group having a carbonyl group attached to the 2, 3, or 4 position of the pyridinium ring or the quinolinium ring, or at the 1, 3, or 4 position of the isoquinolinium ring unless otherwise specified. Provided that at least one of R ₄ in the formulas (x ′) and (xi ′) is In the above formula, the position of the group having alkylene, R ₀ , P, R ₁ , dotted line and carbonyl is as defined above. And when at least one of the R ₄ radicals in a given compound is a carbonyl group from above, all of the carbonyl groups in this compound are identical. The compound of claim 33, wherein P is zero. The compound of claim 34, wherein P is zero. The method of claim 33 or 34, wherein P is 1, alkylene is —CH ₂ —, R ₀ is H, —CH ₃ , —CH (CH ₃ ) ₂ , —CH ₂ CH (CH ₃ ) ₂ , ,-(CH ₂ ) ₂ -SCH ₃ , -CH ₂ -CONH ₂ and -CH ₂ CH ₂ -CONH ₂ . A radiopharmaceutical compound having the formula: or a pharmaceutically acceptable nontoxic salt thereof. In the above formula, ○-can chelate with metallic radionuclide and has at least one reactive functional group selected from the group consisting of amino, carboxyl, hydroxyl, imide and imide, A residue in a chelating agent having a non-essential functional group, wherein at least one of the reactive functional groups of the chelating agent has no hydrogen atom, y is 1 or 2, and [DHC] is biooxidized blood Dihydropyridine in reduced form of brain permeability Pyridinium salt redox carrier, M is a metal radionuclide, the radiopharmaceutical compound of formula (III) is a chelate of the compound of the following structural formula and a metal radionuclide. In the above formula, ○-, [DHC] and y are as defined above. 39. The compound of claim 38, wherein at least one of the amino or hydroxyl reactive functional groups of the chelating agent is free of one hydrogen atom. 40. The compound of claim 39, wherein y is one. 40. The compound of claim 39, wherein [DHC] is a radical of the formula: In the above formula, the alkylene group is one to three linear or branched carbon atoms, R ₀ is the same radical as the corresponding part of the natural amino acid, and P is 0, 1 or 2, and P is 2 , The alkylene groups are the same or different and the R ₀ radicals are the same or different, and the dotted lines in the formulas (a '), (b') and (c ') are doubled at either the 4 or 5 position of the dihydropyridine ring. The presence of one bond, and the dashed lines in the structural formulas (d '), (e') and (f ') indicate that there is a double bond in either the 2 or 3 position of the dihydroquinoline ring. And R ₁ is C ₁ -C ₇ alkyl, C ₁ -C ₇ haloalkyl or C ₇ -C ₁₀ aralkyl, R ₃ is C ₁ -C ₃ alkylene, and X is -CONR′R ″ where R ′ And R ″ are the same or different and are each H or C ₁ -C ₇ alkyl) or -CH = NOR ″ where R ″ is H or C ₁ -C ₇ alkyl. In addition, the group having a carbonyl group of the formulas (a ') and (c') and the X substituents of the formula (b ') are each bonded to the 2, 3 or 4 position of the hydrohydropyridine ring, and the formulas (d') and ( f ′) group with carbonyl and X substituent of structure (e ′) are bonded to the 2,3 or 4 position of the hydroquinolin ring, respectively, and have carbonyl of formula (g ′) and (j ′) The X substituent of the group and the structural formula (h ') is bonded to the 1, 3 or 4 position of the hydrohydroisoquinoline ring, respectively. 42. The radiopharmaceutical compound according to claim 41, wherein P is zero. 42. The compound of claim 41 wherein P is 1, alkylene is -CH _2- , R ₀ is H, -CH ₃ , -CH (CH ₃ ) ₂ , -CH ₂ CH (CH ₃ ) ₂ , ,-(CH ₂ ) -SCH ₃ , -CH ₂ -CONH ₂ or -CH ₂ CH ₂ -CONH ₂ . 39. A radiopharmaceutical compound with a moiety as defined in claim 38 wherein there is no one hydrogen atom in the -NH- component which is part of an amide functional group or an imide functional group or part of a primary or secondary amino functional group having a low pKa. . 45. The radiopharmaceutical compound according to claim 44, wherein y is one. 45. The radiopharmaceutical compound according to claim 44, wherein [DHC] is a radical of the structure: In the above formula, the alkylene group is one to three linear or branched carbon atoms, R ₀ is the same radical as the corresponding part of the natural amino acid, and P is 0, 1 or 2, and P is 2 , The alkylene groups are the same or different and the R ₀ radicals are the same or different and R is hydrogen, C ₁ -C ₇ alkyl, C ₃ -C ₈ cycloalkyl, C ₁ -C ₇ haloalkyl, furyl, phenyl or Halo, lower alkyl, lower alkoxy, carbamoyl, lower alkoxycarbonyl, lower alkanoyloxy, lower alloalkyl, mono (lower alkyl) carbamoyl, di (lower alkyl) carbamoyl, lower alkylthio, lower Phenyl substituted with alkylsulfinyl or loweralkylsulfonyl. And the dotted lines in the structural formulas (k '), (l') and (m ') indicate that there is a double bond in either the 4 or 5 position of the dihydropyridine ring, and the structural formulas (n'), (o ') The dashed lines in) and (p ′) indicate that there is a double bond in either the 2 or 3 position of the dihydroquinoline ring, and R ₁ is C ₁ -C ₇ alkyl, C ₁ -C ₇ haloalkyl or C ₇ -C ₁₀ aralkyl, R ₃ is C ₁ -C ₃ alkylene, X is -CONR′R ″ where R ′ and R ″ are the same or different and each is H or C ₁ -C ₇ alkyl CH—NOR ″ where R ″ is H or C ₁ -C ₇ alkyl. In addition, the group having a carbonyl group of the structural formula (k ') and (m') and the X substituent of the structural formula (l ') are each bonded to the 2, 3 or 4 position of the dihydropyridine ring, and the structural formula (n') The group having a carbonyl group of (p ′) and the X substituent of the formula (o ′) are each bonded to the 2, 3 or 4 positions of the dihydroquinoline ring, and have a carbonyl group of the formulas (q ′) and (s ′). The X substituents of the group and of the formula (r ′) are bonded at the 1, 3 or 4 positions of the dihydroisoquinoline ring, respectively. 47. The radiopharmaceutical compound according to claim 46, wherein P is zero. 47. The compound of claim 46 wherein P is 1, alkylene is -CH _2- , R ₀ is H, -CH ₃ , -CH (CH ₃ ) ₂ , -CH ₂ CH (CH ₃ ) ₂ , ,-(CH ₂ ) ₂ -SCH ₃ , -CH ₂ -CONH ₂ or -CH ₂ CH ₂ -CONH ₂ . 39. A radiopharmaceutical compound with a moiety according to claim 38 wherein at least one carboxyl reactive functional group of the chelating agent is free of one hydrogen atom. The radiopharmaceutical compound according to claim 49, wherein Y is one. The radiopharmaceutical compound according to claim 49, wherein [DHC] is a radical of the structure: In the above formula, the alkylene group is one to three linear or branched carbon atoms, R ₀ is the same radical as the corresponding part of the natural amino acid, and P is 0, 1 or 2, and P is 2 , The alkylene groups are the same or different and the R ₀ radicals are the same or different, and the dashed lines in the formulas (i '), (ii') and (iii ') are doubled at either 4 or 5 positions of the dihydropyridine ring. A dotted line in the formulas (iv '), (v') and (vi ') indicates that there is a double bond in either the 2 or 3 position of the dihydroquinoline ring, Z' is C _1- C ₈ straight or branched alkylene, Q is -0- or -NH-, R ₁ is C ₁ -C ₇ alkyl, C ₁ -C ₇ haloalkyl or C ₇ -C ₁₀ aralkyl , R ₃ is C ₁ -C ₃ alkylene, X is -CONR′R ″ (where R ′ and R ″ are the same or different and each is H or C ₁ -C ₇ alkyl) or -CH = NOR ″ (where R ″ is H or Is C ₁ -C ₇ alkyl). And the group having a C substituent of formula (ii ') and a carbonyl group of formulas (i') and (iii ') are each bonded to the 2, 3, or 4 positions of the dihydropyridine ring, and The group having the X substituent and the carbonyl of the formulas (iv ') and (vi') is bonded at the 2, 3 or 4 position of the dihydroquinoline ring, respectively, and has the formula (viii ') and the X substituent and the structure (vii'). And carbonyl groups of (ix ′) are attached at the 1, 3, or 4 position of the dihydroisoquinoline ring. 51. The radiopharmaceutical compound according to claim 50, wherein [DHC] is a radical of the formula: In the above formula, the alkylene group is one to three linear or branched carbon atoms, R ₀ is the same radical as the corresponding part of the natural amino acid, and P is 0, 1 or 2, and P is 2 , Alkylene groups are the same or different, R ₀ radicals are the same or different, and the dotted line in formula (xi ′) indicates that there is a double bond in either the 4 or 5 position of the dihydropyridine ring, and the structural formula (xiii Dashed line in ′) indicates that there is a double bond in either the 2 or 3 position of the dihydroquinoline ring, Is the skeleton of the sugar molecule, n ^iv is an integer positive (+) equal to the total number of -OH groups of the sugar molecule from which this skeleton is derived, and n ^v is greater than the total number of -OH groups of the sugar molecule from which this skeleton is derived. One less positive integer. And A in structural formulas (ⅹii '), (xii'), (xiv ') and (xiv ″) are hydroxy or D', respectively, and D 'is hydrogen in the chelating -COOH functional group having one reactive -COOH functional group. A residue characterized by the absence of one atom. And R ₄ in the formulas (x ') and (xi') are each hydroxy or one of the following: In the above formula, the alkylene group is a straight or branched carbon atom having 1 to 3 carbon atoms, R ₀ is the same radical as the corresponding part of the natural amino acid, P is 0, 1, or 2, P is 2 Where alkylene groups are the same or different and the R ₀ radicals are the same or different, the dashed lines are as defined in formulas (xii '), (xiii'), and D 'is the formulas (xii', (xiii ') and (xiv ″), and R ₁ is C ₁ -C ₇ alkyl, C ₁ -C ₇ haloalkyl or C ₁ -C ₇ aralkyl and the groups having carbonyl are pyridinium rings or quinoli To the 2, 3, or 4 position of the chromium ring, respectively, and to the 1, 3 or 4 position of the isoquinolinium ring, respectively, unless otherwise specified, provided that the structural formulas (x ') and (xi') At least R ₄ one is The position of the group having alkylene, R ₀ , P, P ₁ , dashed line and carbonyl in the above formula is as defined above, and at least one R ₄ radical in a given compound is preceded by carbonyl In the case of a group having a carbonyl group in the compound, all groups are identical. 52. The radiopharmaceutical compound according to claim 51, wherein P is zero. The radiopharmaceutical compound according to claim 52 wherein P is zero. 53. The compound of claim 51 or 52 wherein P is 1, alkylene is -CH _2- , R ₀ is H, -CH ₃ , -CH (CH ₃ ) ₂ , -CH ₂ CH (CH ₃ ) ₂ , ,-(CH ₂ ) ₂ -SCH ₃ , -CH ₂ -CONH ₂ or -CH ₂ CH ₂ -CONH ₂ radiopharmaceutical compound. The radiopharmaceutical compound according to claim 38, wherein M is technetium -99 _m . A radiopharmaceutical compound having the following structural formula (IV) and being a chelating agent of the salt of the structural formula (I) with a metallic radionuclide. In the above expression -Can form chelates with metallic radionuclides and have one canceled reactive functional group selected from the group consisting of amino, carboxyl, hydroxyl, amide and amides but not essential to the complex formation properties of the chelate; A moiety in the chelating agent, characterized in that at least one of the reactive functional groups of the chelating agent lacks a single atom, Y is 1 or 2, and [QC ⁺ ] is in the form of a hydrophilic and ionic pyridinium salt. Dihydropyridine A pyridinium salt redox carrier, X ⁻ is an anion of a pharmaceutically acceptable inorganic or organic acid, m is a number multiplied by n, and M is a metallic radionuclide. 59. A radiopharmaceutical compound with a moiety as claimed in claim 57 wherein at least one amino or hydroxyl reactive functional group of the chelating agent is free of one hydrogen atom. 59. A radiopharmaceutical compound according to claim 58, wherein Y is 1. 59. The radiopharmaceutical compound according to claim 58, wherein [QC ⁺ ] is a radical of the structure: In the above formula, the alkylene group is one to three linear or branched carbon atoms, R ₀ is the same radical as the corresponding part of the natural amino acid, and P is 0, 1 or 2, and P is 2 Alkylene groups are the same or different and R ₀ radicals are the same or different, R ₁ is C ₁ -C ₇ alkyl, C ₁ -C ₇ haloalkyl, or C ₁ -C ₁₀ aralkyl, and R ₃ is C ₁ -C ₃ alkylene, where X is -CONR'R "(where R 'and R" are the same or different and each is H or C ₁ -C ₇ alkyl) or -CH = NOR "' where R"'is H Or C ₁ -C ₃ alkyl). And the group having a carbonyl group of formulas (a) and (c) and the X substituent group of formula (b) are each bonded at the 2, 3 or 4 position of the pyridinium ring, and the carbon of the formulas (d) and (f) X-substituents of the group having the carbonyl and the formula (e) are bonded to the 2, 3, or 4 position of the quinolidium ring, respectively, the group having the carbonyl of the formula (g) and (j) and X of the formula (h) The substituent is bonded at the 1, 3, or 4 position of the isoquinolinium ring. 61. The radiopharmaceutical compound according to claim 60, wherein P is zero. 61. The compound of claim 60 wherein P is 1, alkylene is -CH _2- , R ₀ is H, -CH ₃ , -CH (CH ₃ ) ₂ , -CH ₂ -CH (CH ₃ ) ₂ , ,-(CH ₂ ) ₂ -SCH ₃ , -CH ₂ -CONH ₂ or -CH ₂ CH ₂ -CONH ₂ . 59. A radiopharmaceutical compound with a moiety as defined in claim 57 wherein there is no one hydrogen atom in the -NH- component which is part of an amide functional group or an imide functional group or is a primary or secondary amino functional group having a low pka. 64. The radiopharmaceutical compound according to claim 63, wherein Y is one. 64. The radiopharmaceutical compound according to claim 63, wherein [QC ⁺ ] is a radical of the structure: In the above formula, the alkylene group is one to three linear or branched carbon atoms, R ₀ is the same radical as the corresponding part of the natural amino acid, and P is 0, 1 or 2, and P is 2 Alkylene groups are the same or different and R ₀ radicals are the same or different, R ₁ is C ₁ -C ₇ alkyl, C ₁ -C ₇ haloalkyl, or C ₇ -C ₁₀ aralkyl, R is hydrogen, C _1- C ₇ alkyl, C ₃ -C ₈ cycloalkyl, C ₁ -C ₇ haloalkyl, furyl, phenyl or one or more halo, lower alkyl, lower alkoxy, carbamoyl, lower alkoxycarbonyl, lower alkanoyloxy, Phenyl substituted with lower haloalkyl, mono (lower alkyl) carbamoyl, di (lower alkyl) carbamoyl, lower alkylthio, lower alkylsulfinyl or lower alkylsulfonyl, R ₃ is C ₁ -C ₃ Alkylene, X is -CONR′R ″ (where R ′ and R ″ are the same or different and are each H or C ₁ -C ₇ alkyl) or -CH = NOR ″ ′ where R ″ ′ is H or Is C ₁ -C ₇ alkyl). And the group having a carbonyl group of the formulas (k) and (m) and the X substituent group of the formula (1) are each bonded at the 2, 3 or 4 position of the pyridinium ring, and the carbon of the formulas (m) and (p) X substituents of the group having a carbonyl and formula (o) are bonded to the 2, 3, or 4 position of the chinolinium ring, respectively, and a group having a carbonyl group of the formula (g) and (s) X substituents are bonded to the 1, 3, or 4 position of the isoquinolinium ring, respectively. 66. The radiopharmaceutical compound according to claim 65, wherein P is zero. 66. The compound of claim 65 wherein P is 1, alkylene is -CH _2- , R ₀ is H, -CH ₃ , -CH (CH ₃ ) ₂ ′, -CH ₂ -CH (CH ₃ ) ₂ , ,-(CH ₂ ) ₂ -SCH ₃ , -CH ₂ -CONH ₂ or -CH ₂ -CH ₂ -CONH ₂ . 58. The radiopharmaceutical compound with a moiety according to claim 57, wherein there is no one hydrogen atom in at least one carboxyl reactive functional group of the chelating agent. The radiopharmaceutical compound according to claim 68, wherein Y is one. The radiopharmaceutical compound according to claim 68, wherein [QC ⁺ ] is a radical of the structure: In the above formula, the alkylene group is one to three linear or branched carbon atoms, R ₀ is the same radical as the corresponding part of the natural amino acid, and P is 0, 1 or 2, and P is 2 Alkylene groups are the same or different and R ₀ radicals are the same or different, Z ′ is C ₁ -C ₈ straight or branched alkylene, Q is —0- or —NH— and R ₁ is C ₁ -C ₇ alkyl, C ₁ -C ₇ haloalkyl, or C ₇ -C ₁₀ aralkyl, R ₃ is C ₁ -C ₃ alkylene, X is -CONR′R ″ where R ′ and N ″ are The same or different and are each H or C ₁ -C ₇ alkyl) or -CH = NOR ″ ′ where R ″ is H or C ₁ -C ₇ alkyl. And the group having an X substituent of formula (ii) and a carbonyl group of formulas (i) and (iii) are each bonded to the 2, 3, or 4 position of the pyridinium ring, and the X substituent of formula (v) The groups having carbonyls of iv) and (vi) are each bonded at the 2, 3 or 4 positions of the quinolinium ring, and the X substituents of formula (viii) and carbonyl of formulas (vii) and (ix) Group is bonded to the 1, 3, or 4 position of the isoquinolinium ring, respectively. The radiopharmaceutical compound according to claim 69, wherein [QC ⁺ ] is a radical of the structure: In the above expression Is the skeleton of the sugar molecule, n ^iv is a positive integer equal to the total number of -OH groups of the sugar molecule from which the biskeleton is derived, and n ^v is the number of -OH groups of the sugar molecule from which the skeleton is induced. One less positive integer, and A in structural formulas (xii), (xiii) and (xiv) are each hydroxy or D ', where D' is a -COOH functional group of the chelating agent with one reactive -COOH functional group. It is a residue characterized by the absence of one hydrogen atom. And R ₄ ′ in structural formulas (x) and (xi) are each hydroxy or one of the following. In the above formula, the alkylene group is one to three linear or branched carbon atoms, R ₀ is the same radical as the corresponding part of the natural amino acid, and P is 0, 1 or 2, and P is 2 Alkylene groups are the same or different and R ₀ radicals are the same or different, D 'is as defined in formulas (xii), (xiii) and (xiv), and R ₁ is C ₁ -C ₇ alkyl, C _7- C ₁ haloalkyl, or C ₇ -C ₁₀ aralkyl, the group having carbonyl being combined at the 2, 3, or 4 position of the pyridinium ring or the quinolinium ring, or the 1, 3 of the isoquinolinium ring, respectively , Or 4 positions. And at least one R ₄ 'in each of the formulas (x) and (xi) is one of: The position of the group having alkylene, R ₀ , P and R ₁ and carbonyl in the above formula is as defined above. And when one or more R ₀ radicals in a given compound are the aforementioned carbonyl group, all of the carbonyl groups of the compound are identical. 71. The radiopharmaceutical compound according to claim 70, wherein P is zero. 76. The radiopharmaceutical compound according to claim 71, wherein P is zero. 71. The compound of claim 70 wherein P is 1, alkylene is -CH _2- , R ₀ is H, -CH ₃ , -CH (CH ₃ ) ₂ ′, -CH ₂ -CH (CH ₃ ) ₂ , ,-(CH ₂ ) ₂ -SCH ₃ , -CH ₂ -CONH ₂ or -CH ₂ CH ₂ -CONH ₂ . 58. The radiopharmaceutical compound according to claim 57, wherein M is technetium-99m. 61. The compound of claims 5, 23, 41 or 60, wherein R ₁ is methyl. 61. The compound of claims 5, 23, 41 or 60, wherein R ₃ is -CH ₂ CH _2- . 61. The compound of claims 5, 23, 41 or 60, wherein X is -CONH ₂ . 61. The compound according to claim 5, 23, 41 or 60, wherein the group having X and carbonyl having different ring positions is the 3-position of the pyridinium ring or the dihydropyrin ring, the quinolinium ring or 3 position of the dihydroquiniline ring system, or isoquinolinium ring or a compound located at the 4 position of the dihydroisoquinolinium ring. 61. The compound of claim 5, 23, 41 or 60, wherein the carrier component is a radical of formula (a) or formula (a '). 81. The sulfide of claim 80, wherein the carrier component is a radical of the formula: 66. The compound of claims 10, 28, 46 or 65, wherein R ₁ is methyl. 66. The compound according to claim 10, 28, 46 or 65, wherein the group having X and carbonyl having different ring positions is the 3-position of the pyridinium ring or the dihydropyridine ring, the quinolinium ring or A compound at position 3 of the dihydroquinoline ring system or at position 4 of the isoquiniumlinium ring or the dihydroisoquinoline ring. 66. The compound of claim 10, 28, 46 or 65 wherein R is hydrogen, C ₁ -C ₇ alkyl, C ₃ -C ₈ cycloalkyl, C ₁ -C ₇ haloalkyl, furyl or phenyl Phosphorus compounds. 70. A compound according to claim 15, 33, 51 or 70 wherein Z 'is C ₁ -C ₃ straight or branched alkylene. Claims according to claim 85 wherein, Z 'is C ₂ -C ₃ straight or alkylene compound in the side chain. 70. The compound according to claim 15, 33 or 51 or 70, wherein the group having X and carbonyl having different ring positions is the 3-position of the pyridinium ring or dihydropyridine ring, the quinolinium ring or the di A compound at position 3 of the hydroquinoline ring system or at position 4 of the isoquinolinium ring or dihydroisoquinoline ring system. 72. The group of claims 16, 34, 52, 71, wherein the group having carbonyl included in the definition of R ₄ and R ₄ ′ is the 3-position of the pyridium or dihydropyridine ring, quinoli. A compound located at the 3 position of the nium ring or the dihydroquinoline ring or at the 4 position of the isoquinolinium ring or the dihydroisoquinoline ring system. 18. A salt according to claim 5, 6 or 17 having the structure: In the above formula, R ₅ is each H or C ₁ -C ₇ alkyl or R ₅ is adjacent When combined with end R ₆ is each H or C ₁ -C ₇ alkyl or one adjacent R ₆ When combined with X ⁻ is an anion of a pharmaceutically acceptable organic or inorganic acid, n is the valence of the acid anion, m ′ is a number equal to 1 when multiplied by n, Is the following radical: In the above formula, R ₇ is H or C ₁ -C ₇ alkyl, respectively, and (alk) has 1, 2, or 3 additional oxygen atoms in the chain, and these oxygen atoms are not adjacent to each other and -A _1- Non-adjacent, straight or branched lower alkylene groups, s is 0 or 1, -A ₁ -is -NH-, -C- or Wherein R ₈ is C ₁ -C ₇ alkyl and [QC ⁺ ] is as defined in claims 5, 6 or 7. A salt according to claim 10 having the structure In the above formula, R ₅ is each H or C ₁ -C ₇ alkyl or R ₅ is adjacent When combined with end R ₆ is each H or C ₁ -C ₇ alkyl or one adjacent R ₆ When combined with X ⁻ is an anion of a pharmaceutically acceptable organic or inorganic acid, n is the valence of the acid anion, m ′ is a number equal to 1 when multiplied by n, Is the following radical: In the above formula, R ₇ is H or C ₁ -C ₇ alkyl, respectively, and (alk) has 1, 2, or 3 additional oxygen atoms in the chain, and these oxygen atoms are not adjacent to each other and -A _2- Non-adjacent, straight or branched lower alkylene group, s is 0 or 1, -A ₂ -is -CONH- or Wherein R ₆ is C ₁ -C ₇ alkyl and [QC ⁺ ] is as defined in claim 10. The salt of claim 15 having the formula In the above formula, R ₅ is each H or C ₁ -C ₇ alkyl or R ₅ is adjacent When combined with end R ₆ is each H or C ₁ -C ₇ alkyl or one adjacent R ₆ When combined with X ⁻ is an anion of a pharmaceutically acceptable organic or inorganic acid, n is the valence of the acid anion, m ′ is a number equal to 1 when multiplied by n, Is the following radical: In the above formula, R ₇ is H or C ₁ -C ₇ alkyl, respectively, and (alk) has 1, 2, or 3 additional oxygen atoms in the chain, and these oxygen atoms are not adjacent to each other and -A _3- Non-adjacent, straight or branched lower allene group, s is 0 or 1, -A ₃ -is -COO- and [QC ⁺ ] is as defined in claims 15 or 16. 8. A salt according to claim 5, 6 or 7, having the structure Wherein R ¹ and R ² are each H or C ₁ -C ₃ alkyl, n ′ is an integer of 0-3 and [QC ⁺ ] is as defined in claims 5, 6 or 7 same. 8. A salt according to claim 5, 6 or 7, having the structure [QC ⁺ ] in the above formula is as defined in claim 5, 6 or 7. A compound according to claim 23, 24 or 25 having the structure In the above formula, R ₅ is each H or C ₁ -C ₇ alkyl or R ₅ is adjacent When combined with Is R ₆ is each H or C ₁ -C ₇ alkyl or one adjacent R ₆ When combined with Represented by Is a radical of the formula In the above formula, R ₇ is H or C ₁ -C ₇ alkyl, respectively, and (alk) has 1, 2, or 3 additional oxygen atoms in the chain, and these oxygen atoms are not adjacent to each other and -A _1- Non-adjacent, straight or branched lower alkylene group, s is 0 or 1, -A ₁ -is -NH-, -C- or -Wherein R ₈ is C ₁ -C ₇ alkyl and [DHC] is as defined in claims 23, 24 or 25. The compound of claim 28 having the structure Wherein R ₅ is each H or C ₃ -C ₇ alkyl or one adjacent R ₅ When combined with Is R ₆ is each H or C ₁ -C ₇ alkyl or one adjacent R ₆ When combined with Represented by Is a radical of the formula In the above formula, R ₇ is H or C ₁ -C ₇ alkyl, respectively, and (alk) has 1, 2, or 3 additional oxygen atoms in the chain, and these oxygen atoms are not adjacent to each other and -A _2- Non-adjacent, straight or branched lower alkylene group, s is 0 or 1, -A ₂ -is -CONH-, or -Wherein R ₉ is C ₁ -C ₇ alkyl and [DHC] is as defined in claim 28. 35. A compound according to claim 33 or 34 having the formula In the above formula, R ₅ is each H or C ₁ -C ₇ alkyl or R ₅ is adjacent When combined with Is R ₆ is each H or C ₁ -C ₇ alkyl or one adjacent R ₆ When combined with Represented by Is a radical of the formula In the above formula, R ₇ is H or C ₁ -C ₇ alkyl, respectively, and (alk) has 1, 2, or 3 additional oxygen atoms in the chain, and these oxygen atoms are not adjacent to each other and -A _2- Non-adjacent, straight or branched lower alkylene groups, s is 0 or 1, -A ₃ -is -COO- and [DHC] is as defined in claims 33 or 34. A compound according to claim 23, 24 or 25 having the structure Wherein R ¹ and R ² are each H, C ₁ -C ₇ alkyl, n ′ is an integer of 0-3 and [DHC] is as defined in claims 23, 24 or 25. 26. A salt according to claim 23, 24 or 25 having the structure [DHC] in the above formula is as defined in claims 23, 24 or 25. 44. The radiopharmaceutical compound according to claim 41, 42 or 43, which is a chelate of a compound having the following structural formula and a metallic radionuclide. In the above formula, R ₅ is each H or C ₁ -C ₇ alkyl or R ₅ is adjacent When combined with Is R ₆ is each H or C ₁ -C ₇ alkyl or one adjacent R ₆ When combined with Represented by Is a radical of the formula In the above formula, R ₇ is H or C ₁ -C ₇ alkyl, respectively, and (alk) has 1, 2, or 3 additional oxygen atoms in the chain, and these oxygen atoms are not adjacent to each other and -A _1- Non-adjacent, straight or branched lower alkylene group, s is 0 or 1, -A ₂ -is -NH-,-O-, or -Wherein R ₈ is C ₁ -C ₇ alkyl and [DHC] is as defined in claims 41, 42 or 43. 47. A radiopharmaceutical compound according to claim 46, which is a chelate of a compound of the following structural formula with a metallic radionuclide. In the above formula, R ₅ is each H or C ₁ -C ₇ alkyl or R ₅ is adjacent When combined with end R ₆ is each H or C ₁ -C ₇ alkyl or one of R ₆ When combined with Represented by Is a radical of the formula O. Wherein R ₇ is each H or C ₁ -C ₇ alkyl, and (alk) has one, two or three additional oxygen atoms in the chain, which are not adjacent to each other and are also adjacent to -A _2- Lower alkylene group having a straight or branched chain, s is 0 or 1, -A ₂ -is -CONH-, or Wherein R ₉ is C ₁ -C ₇ alkyl and [DHC] is as defined in claim 46. 52. The radiopharmaceutical compound according to claim 51 or 52, which is a chelate of the following structural formula C compound with a metallic radionuclide. In the above formula, R ₅ is each H or C ₁ -C ₇ alkyl or one of R ₅ | When combined with Is R ₆ is each H or C ₁ -C ₇ alkyl or one adjacent R ₆ When combined with Is Represented by Is a radical of the formula In the above formula, R ₇ is H or C ₁ -C ₇ alkyl, respectively, and (alk) has 1, 2 or 3 additional oxygen atoms in the chain, which are not adjacent to each other and are also adjacent to -A _3- And a straight or branched lower alkylene group, s is 0 or 1, -A ₃ -is -COO-, and [DHC] is as defined in claims 51 or 52. 104. The radiopharmaceutical compound according to claim 99, wherein the metallic radionuclide is oxotechnate -99m ion. 101. The radiopharmaceutical compound according to claim 100, wherein the metallic radial nuclide is oxotechnate -99 m ion. 102. The radiopharmaceutical compound according to claim 101, wherein the metallic radionuclide is oxotechnate -99 m ion. 44. The radiopharmaceutical compound according to claim 41, 42 or 43, wherein the compound of the formula and metal is a chelate of the radionuclide. Wherein R ¹ and R ² are each C ₁ -C ₃ alkyl, n ′ is an integer of 0-3 and [DHC] is as defined in claims 41, 42 or 43. 105. The radiopharmaceutical compound according to claim 105, wherein the metallic radionuclide is oxotechnate -99 m ion. 44. A radiopharmaceutical compound according to claim 41, 42 or 43 which is a chelate of a compound of the following structural formula with a radioactive radionuclide. [DHC] in the above formula is as defined in claims 41, 42 or 43. 108. The radiopharmaceutical compound according to claim 107, wherein the metallic radionuclide is oxotechnate -99 m ion. 63. A radiopharmaceutical compound according to claim 60, 61 or 62 which is a chelate of a salt of the following structural formula with a metallic radionuclide. In the above formula, R ₅ is each H or C ₁ -C ₇ alkyl or R ₅ is adjacent When combined with end R ₆ is each H or C ₁ -C ₇ alkyl or one adjacent R ₆ When combined with X ⁻ is an anion of a pharmaceutically acceptable organic or inorganic acid, 7 is the valence of the acid anion, m ¹ is a number equal to 1 when multiplied by n, Is a radical of the formula In the above formula, R ₇ is H or C ₁ -C ₇ alkyl, respectively, and (alk) has 1, 2 or 3 additional oxygen atoms in the chain, which are not adjacent to each other and are also adjacent to -A _1-. Lower alkylene group having a straight or branched chain, s is 0 or 1, and -A ₁ -is -NH-, -O- or -Wherein R ₈ is C ₁ -C ₇ alkyl and [QC ⁺ ] is as defined in claims 60, 61 or 62. 66. The radiopharmaceutical compound according to claim 65, which is a chelate of a salt of the following structural formula with a metallic radionuclide. In the above formula, R ₅ is each H or C ₁ -C ₇ alkyl or R ₅ is adjacent When combined with Is R ₆ is each H or C ₁ -C ₇ alkyl or one adjacent R ₆ When combined with X ⁻ is an anion of a pharmaceutically acceptable organic or inorganic acid, n is the valence of the acid anion, m ′ is a number equal to 1 when multiplied by n, Is a radical of the formula Wherein R ₇ is each H or C ₁ -C ₇ alkyl, and (alk) has one, two or three additional oxygen atoms in the chain, which are not adjacent to each other and are also adjacent to -A _2- Lower alkylene group having a straight or branched chain, s is 0 or 1, and -A ₂ -is -CONH- or Wherein R ₉ is C ₁ -C ₇ alkyl and [QC ⁺ ] is as defined in claim 65. The radiopharmaceutical compound according to claim 70 or 71, which is a chelate of a salt of the following structural formula with a metallic radionuclide. In the above formula, R ₅ is each H or C ₁ -C ₇ alkyl or R ₅ is adjacent When combined with end R ₆ is each H or C ₁ -C ₇ alkyl or one adjacent R ₆ is When combined with X ⁻ is an anion of a pharmaceutically acceptable organic or inorganic acid, n is the valence of the acid anion, m ′ is a number equal to 1 when multiplied by n, Is a radical of the formula In the above formula, R ₇ is H or C ₁ -C ₇ alkyl, respectively, and (alk) has 1, 2 or 3 additional oxygen atoms in the chain, which are not adjacent to each other and are also adjacent to -A _3- And a straight or branched lower alkylene group, s is 0 or 1, -A ₃ -is -COO- and [QC ⁺ ] is as defined in claims 70 or 71. 109. The radiopharmaceutical compound according to claim 109, wherein the metallic radionuclide is oxotechnate -99 m ion. 117. The radiopharmaceutical compound according to claim 110, wherein the metallic radionuclide is oxotechnate -99 m ion. 112. The radiopharmaceutical compound according to claim 111, wherein the metallic radionuclide is oxotechnate -99 m ion. 63. A radiopharmaceutical compound according to claim 60, 61 or 62 which is a chelate of a salt of the formula with a metallic radionuclide. Wherein R ¹ and R ² are each H or C ₁ -C ₃ alkyl, n ′ is an integer from 0-3 and [QC ⁺ ] is as defined in claims 60, 61 or 62. same. 116. The radiopharmaceutical compound according to claim 115, wherein the metallic radionuclide is oxotechnate -99 m ion. 63. A radiopharmaceutical compound according to claim 60, 61 or 62 which is a chelate of a salt of the formula with a metallic radionuclide. [QC] in the above formula is as defined in claims 60, 61 or 62. 117. The radiopharmaceutical compound according to claim 117, wherein the metallic radionuclide is oxotechnate -99 m ion. The salt of claim 2 having the structure The compound of claim 20 having the structure The radiopharmaceutical compound according to claim 38, which is a complex of an oxotechnate -99m ion with a compound of the formula: 59. The radioactive compound according to claim 57, which is a complex of a salt of the formula: oxotechnate -99m ion. An imaging method of the brain in which a radiopharmaceutical compound according to claim 38 is administered to a patient in an amount sufficient to deliver an imaging effective amount of the radioactive revolution to the brain. In a separate container, (1) the radioactive metal can be reduced to an oxidation state capable of forming a complex with the compound of formula (II) according to claim 20 and (2) the compound of formula (II). Pharmaceutically acceptable sources include a reducing agent and (3) a biologically compatible sterile liquid medium. In a separate container, (1) a salt of formula (I) according to claim 2, (2) a pharmaceutically acceptable reducing agent capable of reducing the salt to a corresponding compound of the following formula, [Wherein [-] and y are as defined in claim 2 and [DHC] is a dihydropyridine reduced form of blood brain barrier permeability to be biooxidized. Pyridinium salt redox carrier, the reducing agent is capable of reducing the radioactive metal to the oxidation state where the compound of formula (II) and the radioactive metal can form a complex compound. (3) for the preparation of injectable radiopharmaceutical compounds comprising biologically compatible sterilized liquid media; 126. The kit of claim 125, wherein the radioactive metal that the reducing agent can reduce is technetium. 126. The kit of claim 125, wherein the reducing agent is sodium adithionate. 126. The kit of claim 125, wherein the pH of the liquid medium is basic. In a separate container, (1) the salt of formula (I) according to claim 2 added in a biologically compatible sterilized liquid medium, and (2) the corresponding compound of formula (II) A kit for the preparation of an injectable radiopharmaceutical compound comprising a pharmaceutically acceptable reducing agent capable of reducing the salt. [Wherein [-] and y are as defined in claim 2 and [DHC] is a dihydropyridine reduced form of blood brain barrier permeability to be biooxidized. Pyridinium salt redox carrier, the reducing agent is capable of reducing the radioactive metal to the oxidation state where the compound of formula (II) and the radioactive metal can form a complex compound. 129. The kit of claim 129, wherein the radioactive metal that the reducing agent can reduce is technetium. 129. The kit of claim 129, wherein the reducing agent is adithionic acid natrum. 129. The kit of claim 129, wherein the pH of the liquid medium is approximately neutral. The kit according to claim 129 (2), comprising a base in addition to a reducing agent. The chelate according to claim 2, having at least one functional group selected from the group consisting of amino, carboxyl, hydroxyl amide, and imide, and also having this functional group being a functional group which is not essential for the complex-forming properties of the chelating agent. The agent or its protected derivative can form a quaternary compound capable of producing a reagent or [QC ⁺ ] radical capable of substituting [QC ⁺ ] radicals with a hydrogen atom from at least one of the reaction functional groups. After reacting with a radical, it is made into a quaternary compound, and when the radical and hydrogen atom capable of producing [QC ⁺ ] radicals are substituted, it is made into a quaternary compound. To form a corresponding salt of formula (I), wherein the structure of formula (I) of claim 2 is Salt preparation method. A process for preparing a compound of formula (II) according to claim 20 which reduces the salt of formula (I) according to claim 2. A method for producing a radiopharmaceutical compound of formula (III) according to claim 38, wherein the complex is formed from a compound of formula (II) according to claim 20 and a metallic radionuclide. A method for producing a radiopharmaceutical compound of formula (III) according to claim 38, wherein the radiopharmaceutical compound of formula (IV) according to claim 57 is reduced. (A) Claims to produce a complex with a salt of formula (I) and a metallic radionuclide according to claim 2, but (b) to oxidize a radiopharmaceutical compound of formula (III) according to claim 38 58. A method for producing a radiopharmaceutical compound of formula (IV). ※ Note: The disclosure is based on the initial application.